Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,421 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Exercise / conversion · Acquired 23,077 · Balance 75,421 F1: Reflects the release of restricted stock units that were previously reported on a Form 4. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Exercise / conversion · Disposed 23,077 · Balance 0 F2: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,970 |
Reported balance
After 2026-06-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-01 · Grant · Acquired 15,970 · Balance 15,970 F2: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2036-06-01 | Direct | 11,069 |
Reported balance
After 2026-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-01 · Grant · Acquired 11,069 · Balance 11,069 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.52 · Expires 2026-06-06 | Direct | 4,269 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,269 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.54 · Expires 2027-05-28 | Direct | 3,448 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 3,448 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.90 · Expires 2028-06-02 | Direct | 3,714 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 3,714 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2029-06-10 | Direct | 13,882 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 13,882 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.82 · Expires 2033-08-10 | Direct | 8,353 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 8,353 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2034-06-01 | Direct | 8,672 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 8,672 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.28 · Expires 2035-06-01 | Direct | 16,107 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 16,107 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the release of restricted stock units that were previously reported on a Form 4.
F2: Once vested, the shares of common stock are not subject to expiration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 23:46 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 15,970 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040573 · wk-form4_1780530371.xml · derivative · entry 4 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,970 Underlying: Common Stock · 15,970 shares Expires not disclosed F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:46 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 11,069 | $0.00 Strike: $10.52 | $0.00 |
DisclosureSEC source: 0001628280-26-040573 · wk-form4_1780530371.xml · derivative · entry 3 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,069 Underlying: Common Stock · 11,069 shares Expires 2036-06-01 Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:46 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 23,077 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040573 · wk-form4_1780530371.xml · derivative · entry 2 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,077 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:46 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 23,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040573 · wk-form4_1780530371.xml · nonDerivative · entry 1 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 23,077 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000129 · wk-form4_1748981284.xml · derivative · entry 4 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,077 Underlying: Common Stock · 23,077 shares Expires not disclosed F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 16,107 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001077183-25-000129 · wk-form4_1748981284.xml · derivative · entry 3 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,107 Underlying: Common Stock · 16,107 shares Expires 2035-06-01 Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 12,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000129 · wk-form4_1748981284.xml · derivative · entry 2 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 12,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000129 · wk-form4_1748981284.xml · nonDerivative · entry 1 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:24 UTC | NEOGENOMICS INC NEO · Entity 2096 | PurchaseCommon Stock | 4,000 | $7.78 | $31,124.40 |
DisclosureSEC source: 0001077183-25-000098 · wk-form4_1746825886.xml · nonDerivative · entry 1 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,090 Read SEC document |
| August 10, 2024 Filed Aug 13, 2024 20:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000129 · wk-form4_1723580855.xml · derivative · entry 2 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,336 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2024 Filed Aug 13, 2024 20:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 11,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000129 · wk-form4_1723580855.xml · nonDerivative · entry 1 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 12,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000093 · wk-form4_1717531712.xml · derivative · entry 9 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,254 Underlying: Common Stock · 12,254 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 8,672 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001077183-24-000093 · wk-form4_1717531712.xml · derivative · entry 8 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,672 Underlying: Common Stock · 8,672 shares Expires 2034-06-01 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000119 · wk-form4_1692049173.xml · derivative · entry 7 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000119 · wk-form4_1692049173.xml · derivative · entry 6 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 00:43 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Options (Right to Buy) · Derivative | 13,882 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001077183-22-000112 · wf-form4_165525376524354.xml · derivative · entry 5 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,882 Underlying: Common Stock · 13,882 shares Expires 2029-06-10 Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 00:43 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 15,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000112 · wf-form4_165525376524354.xml · nonDerivative · entry 1 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,754 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 23:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Options (Right to Buy) · Derivative | 3,714 | $0.00 Strike: $40.90 | $0.00 |
DisclosureSEC source: 0001077183-21-000156 · wf-form4_162285100556937.xml · derivative · entry 4 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,714 Underlying: Common Stock · 3,714 shares Expires 2028-06-02 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 23:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 3,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000156 · wf-form4_162285100556937.xml · nonDerivative · entry 1 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,198 Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:58 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Options (Right to Buy) · Derivative | 3,448 | $0.00 Strike: $28.54 | $0.00 |
DisclosureSEC source: 0001077183-20-000134 · wf-form4_159105226356124.xml · derivative · entry 3 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,448 Underlying: Common Stock · 3,448 shares Expires 2027-05-28 Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:58 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 2,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000134 · wf-form4_159105226356124.xml · nonDerivative · entry 1 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,117 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Options (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000111 · wf-form4_156021586726965.xml · derivative · entry 2 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000111 · wf-form4_156021586726965.xml · nonDerivative · entry 1 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,419 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.